AmiVijayDesaiMDMSCE

PubMed

• 23 citations
  Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
  Kelly C Goldsmith, Julie R Park, Kimberly Kayser, Jemily Malvar, Yueh-Yun Chi, Susan G Groshen, Judith G Villablanca, Kateryna Krytska, Lillian M Lai, Patricia T Achar...> ;Nature Medicine. 2023 May 1
• 9 citations
  Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macro...
  Benjamin J Lerman, Yimei Li, Cecilia Carlowicz, Meaghan Granger, Thomas Cash, Arhanti Sadanand, Katherine Somers, Aeesha Ranavaya, Brian D Weiss, Michelle Choe, Jennif...> ;Journal of Clinical Oncology. 2023 Jan 20
• 7 citations
  Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
  Ami V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, Arlene Naranjo, Wendy B London, Sheena C Tenney, Mitchell Diccianni, Jacquelyn A Hank, Marguerite T Parisi, Barry ...> ;Journal of Clinical Oncology. 2022 Dec 10
• 35 citations
  Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
  Ami V Desai, Giles W Robinson, Karen Gauvain, Ellen M Basu, Margaret E Macy, Luke Maese, Nicholas S Whipple, Amit J Sabnis, Jennifer H Foster, Suzanne Shusterman, Jane...> ;Neuro-Oncology. 2022 Oct 3
• 6 citations
  Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease.
  Ami V Desai, Mark A Applebaum, Theodore G Karrison, Akosua Oppong, Cindy Yuan, Katherine R Berg, Kyle MacQuarrie, Elizabeth Sokol, Anurekha G Hall, Navin Pinto, Ian Wo...> ;Cancer. 2022 Aug 1
• 4 citations
  Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma.
  Skye Balyasny, Sang Mee Lee, Ami V. Desai, Samuel L. Volchenboum, Arlene Naranjo, Julie R. Park, Wendy B. London, Susan L. Cohn, Mark A. Applebaum> ;JAMA Network Open. 2021 Jul 1
• 24 citations
  Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.
  Riyue Bao, Stefani Spranger, Kyle M. Hernandez, Yuanyuan Zha, Peter Pytel, Jason J. Luke, Thomas F. Gajewski, Samuel L. Volchenboum, Susan L. Cohn, Ami V. Desai> ;Journal for Immunotherapy of Cancer. 2021 Jul 1
• 15 citations
  Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors
  Corey C. Foster, Gini F. Fleming, Theodore Karrison, Chih-Yi Liao, Ami V. Desai, John W. Moroney, Mark J. Ratain, Rita Nanda, Blase N. Polite, Olwen Hahn, Peter H. O'D...> ;Clinical Cancer Research. 2021 Jun 24
• 28 citations
  Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma.
  Kira Bona, Yimei Li, Lena E. Winestone, Kelly D. Getz, Yuan-Shung Huang, Brian T. Fisher, Ami V. Desai, Troy Richardson, Matthew Hall, Arlene Naranjo, Tara O. Henderso...> ;Journal of the National Cancer Institute. 2021 Mar 1
• Reply to K. Beiske et al
  Elizabeth A. Sokol, Ami V. Desai, Mark A. Applebaum, Dominique Valteau-Couanet, Julie R. Park, Andrew D.J. Pearson, Gudrun Schleiermacher, Meredith S. Irwin, Michael D...> ;Journal of Clinical Oncology. 2020 Sep 15
• 39 citations
  Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project
  Elizabeth A. Sokol, Ami V. Desai, Mark A. Applebaum, Dominique Valteau-Couanet, Julie R. Park, Andrew D.J. Pearson, Gudrun Schleiermacher, Meredith S. Irwin, Michael D...> ;Journal of Clinical Oncology. 2020 Apr 21
• 14 citations
  Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma.
  Tal Schechter, Evelio Perez-Albuerne, Tiffany F. Lin, Meredith S. Irwin, Mohammed Sh. Essa, Ami V. Desai, Haydar Frangoul, Gregory A. Yanik, L. Lee Dupuis, David A. Ja...> ;Bone Marrow Transplantation. 2020 Mar 1
• 24 citations
  The ganglioside G D2 as a circulating tumor biomarker for neuroblastoma.
  Frank M. Balis, Christine Busch, Ami Vijay Desai, Emily Hibbitts, Arlene Naranjo, Rochelle Bagatell, Meredith S. Irwin, Elizabeth Fox> ;Pediatric Blood & Cancer. 2020 Jan 1
• 8 citations
  Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma.
  Hari K. Narayan, Mary E. Putt, Nikitha Kosaraju, Alejandro Paz, Shivani M. Bhatt, Theodore Plappert, Laura Mercer-Rosa, Saro H. Armenian, Ami V. Desai, Richard B. Wome...> ;Open Heart. 2019 Jun 1
• 69 citations
  The Evolution of Risk Classification for Neuroblastoma
  Elizabeth A. Sokol, Ami V. Desai> ;Children. 2019 Feb 11
• Significance of CNS 2 cerebrospinal fluid status post-induction in pediatric and adolescent patients with acute lymphoblastic leukemia
  Arun Gurunathan, Ami V. Desai, L. Charles Bailey, Yimei Li, John K. Choi, Susan R. Rheingold> ;Pediatric Blood & Cancer. 2019 Jan 1
• 4 citations
  Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.
  Ami V. Desai, Yimei Li, Kelly D. Getz, Alix E. Seif, Brian T. Fisher, Vera Huang, Richard Aplenc, Rochelle Bagatell> ;Pediatric Blood & Cancer. 2018 Dec 1
• 14 citations
  A validated HPLC-MS/MS method for estimating the concentration of the ganglioside, GD2, in human plasma or serum.
  Christine Busch, Ami V. Desai, Ganesh S. Moorthy, Elizabeth Fox, Frank M. Balis> ;Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 2018 Dec 1
• 12 citations
  Clinical Assessment and Diagnosis of Germline Predisposition to Hematopoietic Malignancies: The University of Chicago Experience.
  Ami V. Desai, Melody Perpich, Lucy A. Godley> ;Frontiers in Pediatrics. 2017 Dec 6
• 3 citations
  Behcet Disease Initially Presenting as Deep Venous Thrombosis: A Case Report.
  Arun Gurunathan, David T. Teachey, Kudakwashe R. Chikwava, Char Witmer, Ami V. Desai> ;Journal of Pediatric Hematology/oncology. 2017 Jul 1
• 22 citations
  Emerging and investigational therapies for neuroblastoma
  Mark A. Applebaum, Ami V. Desai, Julia L. Glade Bender, Susan L. Cohn> ;Expert Opinion on Orphan Drugs. 2017 Mar 17
• 30 citations
  Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
  Ami V. Desai, Mallorie B. Heneghan, Yimei Li, Nancy Bunin, Stephan A. Grupp, Rochelle Bagatell, Alix E. Seif> ;Bone Marrow Transplantation. 2016 May 9
• 8 citations
  Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a Nat...
  Ami V. Desai, Alix E. Seif, Yimei Li, Kelly D. Getz, Brian T. Fisher, Vera Huang, Adjoa Mante, Richard Aplenc, Rochelle Bagatell> ;Pediatric Blood & Cancer. 2016 Jan 21
• 17 citations
  Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy.
  Araz Marachelian, Ami V. Desai, Frank M. Balis, Howard M. Katzenstein, Muna Qayed, Michael B. Armstrong, Kathleen A. Neville, Susan L. Cohn, Mark Bush, Rudy Gunawan, A...> ;Cancer Chemotherapy and Pharmacology. 2016 Jan 20
• 22 citations
  Atypical Chronic Myeloid Leukemia in Two Pediatric Patients.
  Jason L. Freedman, Ami V. Desai, L. Charles Bailey, Richard Aplenc, Bettina Burnworth, Barbara K. Zehentner, David T. Teachey, Gerald Wertheim> ;Pediatric Blood & Cancer. 2016 Jan 1
• Join now to see all

Lectures

• Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018